Characterization and Functional Prediction of Bacteria in Ovarian Tissues
October 23rd, 2021
2.5K views
Immunohistochemistry staining and 16S ribosomal RNA gene (16S rRNA gene) sequencing were performed in order to discover and distinguish bacteria in cancerous and noncancerous ovarian tissues in situ. The compositional and functional differences of the bacteria were predicted by using BugBase and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt).
Overview
This protocol is designed to discover and distinguish bacteria in cancerous and non-cancerous ovarian tissues in situ. Immunohistochemistry staining and 16S rRNA sequencing are utilized to predict the compositional and functional differences of the bacteria.
Key Study Components
Area of Science
- Microbiology
- Oncology
- Immunology
Background
- Understanding the bacterial composition in ovarian tissues can provide insights into cancer biology.
- Immunohistochemistry staining allows for the visualization of bacteria in tissue samples.
- 16S rRNA sequencing is a powerful tool for identifying bacterial species.
- Predictive tools like BugBase and PICRUSt can infer bacterial functions based on their genetic information.
Purpose of Study
- To extract and identify bacteria from ovarian tissues.
- To compare bacterial populations in cancerous versus non-cancerous tissues.
- To predict the functional roles of identified bacteria.
Methods Used
- Immunohistochemistry staining for tissue visualization.
- 16S rRNA gene sequencing for bacterial identification.
- BugBase for predicting bacterial composition.
- PICRUSt for predicting functional differences among bacteria.
Main Results
- Identification of distinct bacterial populations in cancerous and non-cancerous ovarian tissues.
- Functional predictions indicate differences in metabolic capabilities between the two tissue types.
- The protocol is adaptable for use with various tumor types.
Conclusions
- This study provides a framework for understanding the role of bacteria in ovarian cancer.
- The methods are accessible and can be implemented in most laboratories.
- Further research may explore the implications of these bacterial communities in cancer progression.
Frequently Asked Questions
What is the significance of studying bacteria in ovarian tissues?
Studying bacteria in ovarian tissues can reveal insights into their role in cancer biology and potential therapeutic targets.
How does immunohistochemistry staining work?
Immunohistochemistry staining uses antibodies to detect specific antigens in tissue sections, allowing visualization of bacteria.
What is 16S rRNA sequencing?
16S rRNA sequencing is a method used to identify and compare bacteria based on their ribosomal RNA genes.
What are BugBase and PICRUSt?
BugBase is a tool for predicting bacterial community composition, while PICRUSt predicts functional capabilities based on genetic data.
Can this protocol be used for other types of tumors?
Yes, the protocol can be adapted to discover bacteria in various tumor types beyond ovarian cancer.
What are the advantages of this protocol?
The protocol is easy to implement and can be performed in most laboratories, making it accessible for researchers.
Executive Industry Relevance
Understanding microbial presence in ovarian tissues addresses a growing need to de-risk cancer target hypotheses by revealing microenvironmental factors that may influence tumor biology. This protocol enables biopharma R&D to assess bacterial contributions to oncogenic pathways, supporting mechanistic insight in early discovery. By providing a standardized method to detect and functionally predict tissue-associated microbes, it aids in prioritizing targets with stronger translational confidence.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates tumor microenvironment hypotheses by identifying bacteria differentially abundant in cancerous versus non-cancerous ovarian tissues.
- Operational Value: Uses immunohistochemistry and 16S rRNA sequencing to spatially resolve and quantify bacterial presence in situ.
- Predictive Value: Employs BugBase and PICRUSt to infer functional phenotypes, such as pathogenicity and oxidative stress tolerance, linked to cancer phenotypes.
Screening & Assay Development
- Assay Readiness: Generates standardized, quantifiable 16S rRNA sequencing outputs suitable for comparative microbial profiling across sample groups.
- Reproducibility: Incorporates contamination controls and sterile tissue handling to ensure reliable detection of true tissue-associated signals.
- Scalability: Compatible with high-throughput sequencing and bioinformatics pipelines for broader application across tumor types.
Translational & Preclinical Research
- Disease Relevance: Detects microbial signatures in human ovarian cancer tissues, supporting relevance to human pathophysiology.
- Translational Continuity: Enables longitudinal tracking of microbial shifts from normal to malignant states, informing biomarker discovery.
- Mechanistic De-risking: Predicts functional microbial contributions (e.g., metabolic pathways) that may modulate tumor progression or therapeutic response.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target hypothesis generation to preclinical validation, particularly in immuno-oncology and microenvironment-focused programs.
- Discovery Biology: Supports hypothesis testing by revealing whether specific bacteria are enriched in tumor tissues and associated with cancer phenotypes.
- Screening: Delivers reproducible, quantitative microbial profiling data that can be integrated with multi-omics datasets for target prioritization.
- Analytics: Provides functional predictions via BugBase and PICRUSt, enabling comparison of metabolic and phenotypic potentials between groups.
- Translational Research: Connects microbial detection to cancer biology through differential abundance and functional inference in patient-derived tissues.
- Enterprise Reuse: Adaptable to other solid tumors, allowing cross-cancer microbiome studies using a standardized workflow.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking microbial presence to functional phenotypes in cancer-relevant pathways.
- Operational Value: Employs accessible techniques (IHC, 16S sequencing, bioinformatics) feasible in most research laboratories.
- Strategic Value: Informs go/no-go decisions by identifying microbial confounders or modulators of tumor biology early in discovery.
- Portfolio Impact: Enables risk-adjusted target selection by accounting for microenvironmental variables that may affect drug efficacy.
Implementation Considerations
- Requires expertise in histology, molecular biology, and bioinformatics for sequencing and functional prediction.
- Necessitates sterile tissue handling, PCR equipment, sequencing platforms, and tools like QIIME, Trimmomatic, and STAMP.
- Demands standardized protocols across sites to minimize contamination and ensure comparability of microbial data.
- Must account for host tissue variability and low biomass challenges when applying to other organ systems.
- Limited by detection sensitivity in low-abundance communities and dependence on reference databases for functional inference.
Biopharma FAQs
Why does 16S rRNA sequencing matter for target validation in ovarian cancer?
16S rRNA sequencing enables detection and comparison of bacterial taxa in cancerous versus non-cancerous ovarian tissues, providing evidence to interrogate microbiome-related hypotheses in target validation.
How does isolating bacterial signals from tissue samples support discovery pipeline integrity?
By using sterile dissection and contamination controls, the protocol ensures that detected signals reflect true tissue-associated microbes, reducing false positives that could mislead target selection.
What do quantitative dependent variable measurements enable in microbial functional prediction?
Relative abundance and diversity indices (e.g., Shannon, Chao1) from 16S sequencing allow statistical comparison of microbial communities between groups, informing functional predictions via BugBase and PICRUSt.
Why do replication requirements matter for cross-functional collaboration in microbiome studies?
Replication across patient samples and technical controls ensures robustness of microbial findings, enabling confident handoff between discovery, translational, and preclinical teams.
What statistical analysis capabilities are required before implementing this protocol in target validation workflows?
The protocol requires Mann-Whitney U, Student’s t-test, and Chi-square tests to assess significant differences in bacterial taxa and confounding factors, supporting reliable biological interpretation.
